Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients
- 1 July 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (7) , 1093-1101
Abstract
Background: HER-2 status is generally determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). Both methods are only semiquantitative, require a tumor sample, and can be difficult to reproduce. We compared these methods with 2 quantitative approaches, one measuring HER-2 gene copy number in tissue by real-time quantitative PCR (qPCR), and the other measuring shed HER-2 protein in serum by ELISA in patients with metastatic disease. Methods: We analyzed 52 cases of metastatic breast cancer for which both serum collected at the diagnosis of metastasis and stored primary breast tumor specimens were available. The within- and between-run imprecision of real-time qPCR and ELISA were evaluated according to Clinical and Laboratory Standards Institute (formerly known as NCCLS) recommendations. Concordance among the 4 methods was assessed by calculating the κ statistic and its 95% confidence interval (95% CI). Results: The CVs for within- and between-run imprecision were both Conclusions: Measurements of HER-2 gene expression by qPCR and of serum HER-2 protein by ELISA are highly reproducible approaches for determining HER-2 status in metastatic breast cancer. In addition, ELISA eliminates the need for biopsy.Keywords
This publication has 26 references indexed in Scilit:
- HER-2 gene amplification can be acquired as breast cancer progressesProceedings of the National Academy of Sciences, 2004
- Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast CancerClinical Cancer Research, 2004
- Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast CarcinomaThe Journal of Molecular Diagnostics, 2004
- Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast CancerClinical Chemistry, 2003
- Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesLaboratory Investigation, 2003
- Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic SettingLaboratory Investigation, 2001
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaLaboratory Investigation, 2000
- Detection of Gene Amplification in Archival Breast Cancer Specimens by Laser-Assisted Microdissection and Quantitative Real-Time Polymerase Chain ReactionThe American Journal of Pathology, 2000
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986